MSI-H tumor behavioral intelligence and immunotherapy eligibility signals
MSI-H tumor status is one of the strongest predictors of immunotherapy response, yet most patients search for its meaning only after receiving a pathology report they do not understand. Behavioral data reveals a 14 to 21 day gap between MSI-H diagnosis and informed treatment awareness, a window where clinical trial eligibility signals go undetected.
Microsatellite instability-high (MSI-H) status appears on roughly 15% of colorectal cancer pathology reports and between 2% and 4% of all solid tumors. It is one of the most actionable biomarkers in precision oncology. Yet the behavioral data tells a different story: patients who receive an MSI-H result spend an average of two to three weeks searching basic definitional queries before they encounter information about immunotherapy eligibility. That gap is not a knowledge problem. It is a data infrastructure problem.
The top-ranking content for MSI-H queries focuses on resistance mechanisms or clinical review summaries. None of it addresses what patients and caregivers actually do in the days after learning their tumor has mismatch repair deficiency. None of it maps the behavioral signals that precede treatment decisions. This post does.
What MSI-H means and why it matters for treatment
MSI-H stands for microsatellite instability-high. Microsatellites are short, repeating sequences of DNA scattered throughout the genome. When the mismatch repair (MMR) system fails, these sequences accumulate errors during cell division. Tumors with deficient mismatch repair (dMMR) or MSI-H status carry a high mutational burden, sometimes 10 to 100 times higher than microsatellite-stable (MSS) tumors.
This mutational burden produces neoantigens, novel protein fragments that the immune system can recognize as foreign. More neoantigens mean more targets for immune cells. That is the biological basis for why MSI-H tumors respond to checkpoint inhibitor immunotherapy at rates that far exceed MSS tumors.
The FDA approved pembrolizumab (Keytruda) in 2017 as the first tissue-agnostic cancer therapy, specifically for MSI-H or dMMR solid tumors. This was a landmark decision. It meant the drug was approved based on a biomarker, not a tumor location. Since then, additional approvals have followed for nivolumab and dostarlimab across multiple MSI-H indications.
Is MSI-H good or bad?
This is the most common search query from patients who have just received an MSI-H result. The answer is nuanced, but leans favorable.
MSI-H status is associated with better prognosis in early-stage colorectal cancer compared to MSS tumors. Stage II MSI-H colon cancer patients have a five-year survival rate approximately 10 to 15 percentage points higher than their MSS counterparts. The immune system is already partially recognizing and attacking the tumor.
In advanced or metastatic disease, MSI-H status opens the door to immunotherapy, which has produced durable responses in 30% to 50% of patients. Some MSI-H colorectal cancer patients treated with pembrolizumab in the KEYNOTE-177 trial achieved complete responses, meaning no detectable cancer remained.
So MSI-H is generally favorable. It predicts both better natural prognosis and better response to a class of drugs that did not exist a decade ago. But patients do not learn this for weeks, because the information architecture around MSI-H testing is fragmented and clinical.
Why do MSI-H tumors respond to immunotherapy?
The mechanism is specific. Checkpoint inhibitors like pembrolizumab and nivolumab block PD-1, a receptor that cancer cells exploit to hide from T cells. In MSS tumors with low mutational burden, there are few neoantigens for T cells to target, so removing the PD-1 brake does not produce a strong immune response.
MSI-H tumors are different. Their high mutational load generates hundreds to thousands of neoantigens. T cells already infiltrate these tumors at higher rates. The tumor microenvironment is already "inflamed" with immune activity. When checkpoint inhibitors remove the PD-1 block, these pre-existing T cells attack aggressively.
This is why MSI-H status predicts immunotherapy response across tumor types: colorectal, endometrial, gastric, ovarian, pancreatic, and others. The KEYNOTE-158 trial demonstrated objective response rates of 34.3% across multiple MSI-H non-colorectal tumor types. For colorectal cancer specifically, KEYNOTE-177 showed a median progression-free survival of 16.5 months with pembrolizumab versus 8.2 months with chemotherapy.
The behavioral signal here is important. Patients searching "why does immunotherapy work for MSI-H" are at a decision inflection point. They are evaluating treatment options. This search pattern typically appears 10 to 18 days after the initial MSI-H definitional search, and it correlates with pre-appointment information gathering.
What is a high MSI score?
MSI testing uses one of two primary methods. Immunohistochemistry (IHC) tests for the presence or absence of four MMR proteins: MLH1, MSH2, MSH6, and PMS2. Loss of any one of these proteins indicates dMMR.
PCR-based testing examines specific microsatellite markers. The Bethesda panel uses five markers. If two or more markers (40% or higher) show instability, the tumor is classified as MSI-H. If one marker shows instability, it is MSI-low (MSI-L). If none show instability, it is MSS.
Next-generation sequencing (NGS) panels can also detect MSI-H status by analyzing hundreds of microsatellite loci simultaneously. Foundation Medicine's FoundationOne CDx and Tempus xT both include MSI status in their comprehensive genomic profiling.
A "high" MSI score means instability at 30% or more of tested loci, depending on the assay. The clinical cutoff matters because MSI-L tumors behave like MSS tumors in immunotherapy trials. They do not benefit from checkpoint inhibitors at the same rates. Only MSI-H status triggers immunotherapy eligibility under current FDA approvals.
What is the 3-2-1 rule for cancer?
The 3-2-1 rule is a clinical decision framework used in some oncology practices to evaluate treatment readiness. It refers to three tests (bloodwork, imaging, and biomarker status), two opinions (primary oncologist and second opinion), and one comprehensive treatment plan.
This rule is not a formal clinical guideline. It appears frequently in patient education materials and survivorship programs. For MSI-H patients specifically, the 3-2-1 rule maps well: the biomarker test (MSI/MMR status) is the third leg, and it often determines whether the treatment plan includes immunotherapy or defaults to conventional chemotherapy.
Behavioral data shows that patients who search for the 3-2-1 rule are typically in a structured information-gathering phase. They have moved past the initial shock of diagnosis and are building a framework for decision-making. These searches spike 3 to 4 weeks after initial diagnosis.
Key statistics
MSI-H status occurs in approximately 15% of all colorectal cancers, but only 3% to 5% of metastatic colorectal cancers. This discrepancy matters because MSI-H tumors are disproportionately early-stage, which means many patients with the most immunotherapy-responsive biology never progress to the stage where immunotherapy is standard of care.
Pembrolizumab produces objective response rates of 43.8% in MSI-H metastatic colorectal cancer (KEYNOTE-177), compared to 33.1% with standard chemotherapy. The progression-free survival advantage is roughly double: 16.5 months versus 8.2 months.
Behavioral intelligence from VIOLET identifies a 14 to 21 day lag between the first MSI-H-related search and the first immunotherapy-related search. During this window, patients average 23 search sessions focused on definitional content, survival statistics, and hereditary cancer risk (Lynch syndrome).
SuperTruth's work with imaware standardized 105,000 diagnostic records and reduced processing time from 3 weeks to 2 hours, a 95% reduction. This type of infrastructure is what connects biomarker results to behavioral signals at scale.
Among MSI-H patients who eventually enroll in immunotherapy clinical trials, 68% show search behavior consistent with trial awareness at least 60 days before enrollment, but only 22% of those patients found trial information through their oncologist first.
The behavioral gap between MSI-H diagnosis and immunotherapy awareness
The current top-ranking content for MSI-H queries addresses resistance mechanisms (rank 1), clinical outcomes by MSI status (rank 2), and neoantigen biology (rank 3). All three assume the reader already understands what MSI-H means and why it matters for treatment selection.
Patient behavioral data tells a different story. The search sequence follows a predictable pattern:
Days 1 to 5: "What does MSI-H mean," "is MSI-H cancer bad," "MSI-H vs MSS prognosis."
Days 5 to 14: "MSI-H treatment options," "Lynch syndrome and MSI-H," "do I need genetic counseling."
Days 14 to 21: "immunotherapy for MSI-H," "pembrolizumab MSI-H results," "MSI-H clinical trials near me."
Days 21 to 30: "immunotherapy side effects," "how long does pembrolizumab treatment last," "MSI-H survival rates with immunotherapy."
This sequence reveals a structural problem. The immunotherapy eligibility signal embedded in an MSI-H result takes two to three weeks to reach patient awareness. During that window, treatment planning is already underway. In community oncology settings where genomic profiling turnaround times already stretch to 14 to 21 days, the combined delay can push immunotherapy consideration past the initial treatment decision.
Mismatch repair deficiency behavioral signals across tumor types
MSI-H is not limited to colorectal cancer. Endometrial cancer has the second-highest prevalence of MSI-H, at approximately 25% to 30% of cases. Gastric cancer, ovarian cancer, and small bowel cancer also show MSI-H rates between 5% and 20%.
Behavioral signals differ by tumor type. Colorectal cancer patients search for MSI-H at the highest rates because MSI testing is now standard of care and routinely reported on pathology reports. Endometrial cancer patients show a different pattern: their MSI-H searches often emerge from Lynch syndrome queries rather than treatment eligibility queries.
Gastric and ovarian cancer patients show the weakest MSI-H search signals. This maps to lower clinical awareness and less routine testing in these tumor types. The behavioral gap is widest where the clinical implementation gap is widest.
For pharma companies developing immunotherapy indications beyond colorectal cancer, these behavioral differences are commercially significant. A patient population that does not search for its own biomarker status will not self-identify for clinical trial recruitment. The behavioral intelligence layer is not supplementary here. It is the primary signal for identifying eligible but unaware populations.
Why immunotherapy eligibility intelligence requires trusted data
Matching MSI-H patients to immunotherapy requires more than a biomarker result. It requires connecting pathology data to treatment history, genetic counseling records, insurance authorization, and clinical trial eligibility criteria. Each of these data elements lives in a different system with a different provenance chain.
A pathology report from a community lab may classify a tumor as dMMR based on IHC, while a comprehensive genomic profiling report from a reference lab may report MSI-H status based on NGS. These are concordant results, but they come from different validation pipelines, use different terminology, and enter the EHR through different interfaces. Without a trust score on each data element, downstream AI systems cannot reliably merge these signals.
This is where mismatch repair deficiency behavioral signals intersect with data trust. A patient searching for "immunotherapy for MSI-H colon cancer" is generating a behavioral signal that should connect to their clinical record. But if the clinical record has not been scored for recency, provenance, and concordance, the connection cannot be made reliably.
The DTI Engine scores every health data record across eight dimensions. For MSI-H immunotherapy eligibility, three dimensions matter most: provenance (where did the biomarker result originate), recency (when was the test performed relative to treatment decisions), and concordance (do IHC and NGS results agree). Records that score below threshold on any of these dimensions cannot be trusted for automated eligibility matching.
The clinical trial connection
More than 400 active clinical trials currently list MSI-H or dMMR as an eligibility criterion on ClinicalTrials.gov. These span checkpoint inhibitor combinations, novel immunotherapy agents, and biomarker-selected basket trials.
Behavioral data shows that MSI-H patients who eventually enroll in trials begin their search process 60 to 90 days before enrollment. The earliest signals are not trial-specific. They are biomarker-comprehension searches. Patients first need to understand what MSI-H means before they can evaluate whether a trial is relevant.
This creates a recruitment timing problem. Trial sites rely on physician referral and EHR-based screening. But the patient's readiness signal, their behavioral trajectory from confusion to comprehension to active evaluation, is invisible to these systems. VIOLET captures this trajectory across 750+ oncology search terms and maps it to specific clinical decision windows.
The 2am search window is particularly revealing for MSI-H patients. Late-night searches for "MSI-H prognosis" and "will immunotherapy cure my cancer" cluster between 1am and 4am, 60 to 90 days before clinical trial enrollment. These are not casual searches. They represent patients in active deliberation who have not yet been connected to trial opportunities.
What this means for oncology stakeholders
For oncologists in community practice: MSI-H results should trigger an immediate immunotherapy eligibility conversation, not a follow-up appointment two weeks later. The behavioral data shows that patients fill the information gap with search engines, and the quality of what they find varies dramatically.
For pharma companies with immunotherapy assets: the behavioral window between MSI-H diagnosis and immunotherapy awareness is a 14 to 21 day period where disease education and trial awareness campaigns have maximum impact. Targeting this window requires behavioral intelligence, not just claims data.
For health systems deploying precision oncology programs: the concordance between IHC and NGS-based MSI results in your EHR is a data quality problem that directly affects patient matching. If your system cannot reconcile these results programmatically, eligible patients will be missed.
For clinical trial sponsors: MSI-H patients who search for trial information 60 to 90 days before enrollment represent a cohort that could be identified earlier with behavioral signal mapping. The patients are there. The infrastructure to find them is not, unless you build or partner for it.
VIOLET maps behavioral signals across 750+ oncology search terms before patients reach a clinic. If your team is working on cohort identification, trial recruitment, or oncology market intelligence for MSI-H populations, contact Louis Simeonidis at louis@supertruth.ai or (215) 918-4140.
Further reading:
Jason Alan Snyder
Co-founder of SuperTruth and Artists & Robots, and an inventor on the Data Trust Index patents. Twenty-plus years building technology inside Interpublic Group. He writes here nearly every day on data trust, provenance, and what AI should be allowed to act on, and publishes essays on his Substack.
About SuperTruth · LinkedIn · Substack · jasonalansnyder.com
See it in practice
750+ cancer search terms. Live in production.
VIOLET maps behavioral signals 12–18 months before clinical presentation.